Indonesian Political, Business & Finance News

Takeda Invests in Plasma Facilities in Indonesia, Targets 2027 Operations

| | Source: investor.id Translated from Indonesian | Investment
Takeda Invests in Plasma Facilities in Indonesia, Targets 2027 Operations
Image: investor.id

JAKARTA — Indonesia has welcomed an investment commitment from Japanese biopharmaceutical company Takeda to develop a plasma-derived medicinal products (PODP) ecosystem in the country.

In the initial phase, Takeda will invest up to US$30 million, or around Rp539 billion, over two years to build a plasma bank network as the foundation for developing a national plasma industry.

Minister of Investment and Downstream Industry/Head of the Investment Coordinating Board (BKPM), Rosan Roeslani, said Takeda’s investment reflects growing confidence among global investors in Indonesia’s investment prospects, particularly in the high-tech healthcare industry.

The investment is a strategic one that brings not only additional capital but also opens opportunities for technology transfer, human resource development, and the creation of highly skilled jobs.

“The government continues to encourage investments that deliver added value and strengthen national industrial capacity, so that Indonesia can become a hub for healthcare manufacturing and innovation in the region,” Rosan said in an official statement received on Tuesday (14 July 2026).

The partnership also aligns with the economic transformation agenda through downstream processing across various strategic sectors, including healthcare, to boost the competitiveness of national industry and strengthen Indonesia’s position in global supply chains. Japan is moreover one of Indonesia’s key strategic investment partners.

According to data from the Ministry of Investment and Downstream Industry/BKPM, Japan ranked as Indonesia’s fifth-largest source of investment in the first quarter of 2026, reaching US$1 billion.

Japan’s total realised investment from 2021 through the first quarter of 2026 reached US$18.1 billion, with average growth of 13.2% and employment totalling 299,460 workers. This provides a strong foundation for developing investment cooperation across priority sectors, including healthcare.

Through this collaboration, the government hopes Indonesia can not only improve public access to much-needed plasma-derived medicinal products, but also build a competitive, innovative and sustainable biopharmaceutical industry ecosystem.

“The first plasma bank is targeted to begin operating in 2027 as part of the development of a national plasma network that meets international standards,” he said.

More from 14 July 2026 →

Cite this article
Source: jawawa.id (https://jawawa.id/newsitem/takeda-invests-in-plasma-facilities-in-indonesia-targets-2027-operations-1784011822)
Originally published by investor.id (https://investor.id/market/446462/takeda-investasi-fasilitas-plasma-di-ri-ditargetkan-mulai-beroperasi-2027), translated from Indonesian
Print